[go: up one dir, main page]

WO2002036562A3 - 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6 - Google Patents

1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6 Download PDF

Info

Publication number
WO2002036562A3
WO2002036562A3 PCT/US2001/045389 US0145389W WO0236562A3 WO 2002036562 A3 WO2002036562 A3 WO 2002036562A3 US 0145389 W US0145389 W US 0145389W WO 0236562 A3 WO0236562 A3 WO 0236562A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclylbenzazoles
hydroxytryptamine
alkylsulfonyl
ligands
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/045389
Other languages
English (en)
Other versions
WO2002036562A2 (fr
Inventor
Michael Gerard Kelly
Derek Cecil Cole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ525592A priority Critical patent/NZ525592A/en
Priority to BRPI0115102-9B1A priority patent/BR0115102B1/pt
Priority to AU2005102A priority patent/AU2005102A/xx
Priority to MXPA03003800A priority patent/MXPA03003800A/es
Priority to CA2426031A priority patent/CA2426031C/fr
Priority to AU2002220051A priority patent/AU2002220051B2/en
Priority to EA200300528A priority patent/EA006205B1/ru
Priority to HU0303756A priority patent/HUP0303756A3/hu
Priority to JP2002539322A priority patent/JP4184077B2/ja
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to EP01992697A priority patent/EP1343756A2/fr
Priority to KR1020037006000A priority patent/KR100822655B1/ko
Priority to IL15544301A priority patent/IL155443A0/xx
Publication of WO2002036562A2 publication Critical patent/WO2002036562A2/fr
Publication of WO2002036562A3 publication Critical patent/WO2002036562A3/fr
Priority to IL155443A priority patent/IL155443A/en
Priority to NO20031977A priority patent/NO326610B1/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne un composé de formule I ainsi que son utilisation dans le traitement thérapeutique de troubles se rapportant ou liés au récepteur de la 5-HT6.
PCT/US2001/045389 2000-11-02 2001-10-31 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6 Ceased WO2002036562A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP2002539322A JP4184077B2 (ja) 2000-11-02 2001-10-31 ５−ヒドロキシトリプトアミン−６リガンドとしての１−アリールまたは１−アルキルスルホニル−ヘテロシクリルベンザゾール
AU2005102A AU2005102A (en) 2000-11-02 2001-10-31 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP01992697A EP1343756A2 (fr) 2000-11-02 2001-10-31 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6
CA2426031A CA2426031C (fr) 2000-11-02 2001-10-31 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6
AU2002220051A AU2002220051B2 (en) 2000-11-02 2001-10-31 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EA200300528A EA006205B1 (ru) 2000-11-02 2001-10-31 1-арил- или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
HU0303756A HUP0303756A3 (en) 2000-11-02 2001-10-31 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands and process for their preparation and pharmaceutical compositions containing them
NZ525592A NZ525592A (en) 2000-11-02 2001-10-31 1-Aryl- or 1-alkylsufonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
MXPA03003800A MXPA03003800A (es) 2000-11-02 2001-10-31 1-aril-o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6.
BRPI0115102-9B1A BR0115102B1 (pt) 2000-11-02 2001-10-31 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
KR1020037006000A KR100822655B1 (ko) 2000-11-02 2001-10-31 5-하이드록시트립타민-6 리간드로서의 1-아릴설포닐- 또는 1-알킬설포닐-헤테로사이클릴벤즈아졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물
IL15544301A IL155443A0 (en) 2000-11-02 2001-10-31 1- aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
IL155443A IL155443A (en) 2000-11-02 2003-04-15 1-Aryl or 1-Alkylsulfonyl - the tricyclylbenzazoles, the process for their preparation and pharmaceutical preparations containing them for the treatment of disorders of the central nervous system affected by 6 HT-5 receptors
NO20031977A NO326610B1 (no) 2000-11-02 2003-04-30 1-aryl- eller 1-alkylsulfonyl-heterocyklylbenzazoler, fremstilling av disse, farmasoytiske preparater inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdom

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24511800P 2000-11-02 2000-11-02
US60/245,118 2000-11-02

Publications (2)

Publication Number Publication Date
WO2002036562A2 WO2002036562A2 (fr) 2002-05-10
WO2002036562A3 true WO2002036562A3 (fr) 2003-01-23

Family

ID=22925357

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045389 Ceased WO2002036562A2 (fr) 2000-11-02 2001-10-31 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6

Country Status (19)

Country Link
US (3) US20020115670A1 (fr)
EP (2) EP2298738B1 (fr)
JP (1) JP4184077B2 (fr)
KR (1) KR100822655B1 (fr)
CN (1) CN1222511C (fr)
AR (1) AR034270A1 (fr)
AU (2) AU2005102A (fr)
BR (1) BR0115102B1 (fr)
CA (1) CA2426031C (fr)
EA (1) EA006205B1 (fr)
HU (1) HUP0303756A3 (fr)
IL (2) IL155443A0 (fr)
MX (1) MXPA03003800A (fr)
NO (1) NO326610B1 (fr)
NZ (1) NZ525592A (fr)
PL (1) PL213134B1 (fr)
TW (1) TWI282787B (fr)
WO (1) WO2002036562A2 (fr)
ZA (1) ZA200304188B (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504395B2 (en) 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
KR101323417B1 (ko) * 2008-11-11 2013-10-29 와이어쓰 엘엘씨 5-히드록시트립타민-6 리간드로서의 1-(아릴술포닐)-4-(피페라진-1-일)-1ｈ-벤즈이미다졸

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032863A1 (fr) 2000-10-20 2002-04-25 Biovitrum Ab N1-(benzensulfonyl)indoles substitues en 2, 3, 4 ou 5 et leur utilisation a des fins de traitement
KR100600240B1 (ko) * 2001-06-07 2006-07-13 에프. 호프만-라 로슈 아게 5-ｈｔ6 수용체 친화도를 갖는 신규한 인돌 유도체
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
ATE331707T1 (de) 2001-06-15 2006-07-15 Hoffmann La Roche 4 piperazinylindolderivate mit affinität zum 5- ht6-rezeptor
GB0203811D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
US7452888B2 (en) 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
EP1513809A1 (fr) * 2002-06-05 2005-03-16 F. Hoffmann-La Roche Ag Derives de 1-sulfonyl-4-aminoalcoxy-indole et leur utilisation comme modulateurs des recepteurs 5-ht6 en traitement de troubles du snc
ES2311721T3 (es) * 2002-09-17 2009-02-16 F. Hoffmann-La Roche Ag Indoles sustituidos en posicion 2,4 y su empleo como moduladores de 5-ht6.
WO2004074243A2 (fr) 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylindazoles utilises comme ligands de la 5-hydroxytryptamine-6
MXPA06000795A (es) 2003-07-22 2006-08-23 Arena Pharm Inc Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo.
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006010629A1 (fr) 2004-07-28 2006-02-02 Glaxo Group Limited Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
JP5146766B2 (ja) * 2005-08-15 2013-02-20 ワイス・エルエルシー ５−ヒドロキシトリプタミン−６リガンドとしての置換−３−スルホニルインダゾール誘導体
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
MX2008010481A (es) 2006-02-17 2008-12-19 Memory Pharm Corp Compuestos que tienen afinado para el receptor f-ht6.
EP2013178A1 (fr) 2006-03-31 2009-01-14 Glaxo Group Limited Dérivés de pipérazine utilisés comme agonistes du récepteur du sécrétagogue de l'hormone de croissance (shc)
AU2007235499A1 (en) * 2006-04-05 2007-10-18 Wyeth Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007120596A1 (fr) * 2006-04-12 2007-10-25 Wyeth DÉRIVÉS DE DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE EN TANT QUE LIGANDS DE 5-HYDROXYTRYPTAMINE-6
CA2672190C (fr) * 2007-01-08 2013-02-05 Suven Life Sciences Limited Composes 4-(heterocyclyl)alkyl-n-(arylsulfonyl)indole et leur utilisation en tant que ligands du 5-ht<sb>6</sb>
EA017007B1 (ru) * 2007-01-08 2012-09-28 Сувен Лайф Сайенсиз Лимитед Соединения 5-(гетероциклил)алкил-n-(арилсульфонил)индола и их применение в качестве лигандов 5-ht
JP2010519226A (ja) * 2007-02-16 2010-06-03 メモリー・ファーマシューティカルズ・コーポレイション ５−ｈｔ６受容体親和性を有する６’位置換インドール及びインダゾール誘導体
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
ATE513810T1 (de) 2007-05-03 2011-07-15 Suven Life Sciences Ltd Aminoalkoxy-aryl-sulfonamidverbindungen und ihre verwendung als 5-ht6-liganden
CA2695456A1 (fr) * 2007-08-15 2009-02-19 Robert Dunn Composes substitues en position 3' ayant une affinite vis-a-vis du recepteur 5-ht<sb>6</sb>
EP2508177A1 (fr) 2007-12-12 2012-10-10 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
WO2010032257A1 (fr) 2008-09-17 2010-03-25 Suven Life Sciences Limited Composés arylindolylsulfonamides et leur utilisation en tant que ligands de 5-ht<sb>6</sb>
CN102159564B (zh) 2008-09-17 2014-06-18 苏文生命科学有限公司 芳基磺酰胺胺化合物及它们作为5-ht6配体的用途
WO2010062321A1 (fr) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées
CA2759491A1 (fr) 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg. Composes de benzenesulfonanilide pour le traitement de troubles repondant a la modulation du recepteur 5-ht6 de la serotonine
BR112012028445A2 (pt) 2010-05-06 2016-07-19 Bristol Myers Squibb Co compostos de heteroarila bicíclica como moduladores de gpr119
MX2012013197A (es) 2010-05-12 2013-04-03 Abbvie Inc Inhibidores de indazol de cinasa.
PL395469A1 (pl) * 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
TWI562990B (en) 2013-08-07 2016-12-21 Cadila Healthcare Ltd Novel compounds as inhibitors of janus kinase
EP3083588B1 (fr) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Composés hétérocycliques aromatiques et leur utilisation dans les produits pharmaceutiques
CN103880750A (zh) * 2014-03-18 2014-06-25 上海皓元生物医药科技有限公司 一种替格列汀关键中间体的制备方法
US9974785B2 (en) * 2014-07-08 2018-05-22 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
RU2719446C2 (ru) * 2014-11-03 2020-04-17 Айомет Фарма Лтд Фармацевтическое соединение
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
EP3322415A4 (fr) 2015-07-15 2019-03-13 Axovant Sciences GmbH Dérivés d'arylhérétoaryl urée en tant que modulateurs du récepteur sérotoninergique 5-ht2a utiles pour la prophylaxie et le traitement d'hallucinations associées à une maladie neurodégénérative
SG11201901146SA (en) * 2016-09-23 2019-04-29 Novartis Ag Indazole compounds for use in tendon and/or ligament injuries
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003400A1 (fr) * 1994-07-26 1996-02-08 Pfizer Inc. Derives 4-indole utilises comme agonistes et antagonistes de la serotonine
EP0930302A2 (fr) * 1998-01-16 1999-07-21 F.Hoffmann-La Roche Ag Dérivés de benzosulfone
WO1999065906A1 (fr) * 1998-06-15 1999-12-23 Allelix Biopharmaceuticals Inc. Piperidine bicyclique et composes de piperazine presentant une affinite pour le recepteur 5-ht¿6?
WO2002008178A1 (fr) * 2000-07-21 2002-01-31 Biovitrum Ab Nouvelle association d'un agoniste de serotonine (5ht2) et d'un antagoniste de serotonine (5ht6) se presentant sous forme de formule pharmaceutique
WO2002032863A1 (fr) * 2000-10-20 2002-04-25 Biovitrum Ab N1-(benzensulfonyl)indoles substitues en 2, 3, 4 ou 5 et leur utilisation a des fins de traitement

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003400A1 (fr) * 1994-07-26 1996-02-08 Pfizer Inc. Derives 4-indole utilises comme agonistes et antagonistes de la serotonine
EP0930302A2 (fr) * 1998-01-16 1999-07-21 F.Hoffmann-La Roche Ag Dérivés de benzosulfone
WO1999065906A1 (fr) * 1998-06-15 1999-12-23 Allelix Biopharmaceuticals Inc. Piperidine bicyclique et composes de piperazine presentant une affinite pour le recepteur 5-ht¿6?
WO2002008178A1 (fr) * 2000-07-21 2002-01-31 Biovitrum Ab Nouvelle association d'un agoniste de serotonine (5ht2) et d'un antagoniste de serotonine (5ht6) se presentant sous forme de formule pharmaceutique
WO2002032863A1 (fr) * 2000-10-20 2002-04-25 Biovitrum Ab N1-(benzensulfonyl)indoles substitues en 2, 3, 4 ou 5 et leur utilisation a des fins de traitement

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504395B2 (en) 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7557109B2 (en) 2001-07-20 2009-07-07 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
KR101323417B1 (ko) * 2008-11-11 2013-10-29 와이어쓰 엘엘씨 5-히드록시트립타민-6 리간드로서의 1-(아릴술포닐)-4-(피페라진-1-일)-1ｈ-벤즈이미다졸

Also Published As

Publication number Publication date
AU2005102A (en) 2002-05-15
CA2426031C (fr) 2011-10-04
NO20031977L (no) 2003-06-30
JP2004513111A (ja) 2004-04-30
CN1222511C (zh) 2005-10-12
NZ525592A (en) 2004-07-30
EA006205B1 (ru) 2005-10-27
TWI282787B (en) 2007-06-21
IL155443A0 (en) 2003-11-23
CN1484638A (zh) 2004-03-24
EP1343756A2 (fr) 2003-09-17
PL213134B1 (pl) 2013-01-31
BR0115102B1 (pt) 2013-11-26
IL155443A (en) 2011-06-30
NO20031977D0 (no) 2003-04-30
ZA200304188B (en) 2004-08-30
MXPA03003800A (es) 2003-08-20
JP4184077B2 (ja) 2008-11-19
HUP0303756A3 (en) 2009-08-28
AU2002220051B2 (en) 2007-05-24
NO326610B1 (no) 2009-01-19
EP2298738A1 (fr) 2011-03-23
KR20030040566A (ko) 2003-05-22
BR0115102A (pt) 2003-09-30
WO2002036562A2 (fr) 2002-05-10
HUP0303756A2 (hu) 2004-03-01
CA2426031A1 (fr) 2002-05-10
EP2298738B1 (fr) 2012-09-19
AR034270A1 (es) 2004-02-18
US20040132741A1 (en) 2004-07-08
US20040087595A1 (en) 2004-05-06
US20020115670A1 (en) 2002-08-22
PL362138A1 (en) 2004-10-18
KR100822655B1 (ko) 2008-04-17
EA200300528A1 (ru) 2003-10-30

Similar Documents

Publication Publication Date Title
WO2002036562A3 (fr) 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6
WO2002051837A3 (fr) Composes heterocyclylindazole et azaindazole utilises en tant que ligands 5-hydroxytryptamine-6
WO2002051832A3 (fr) Composes heterocyclylalkylindole ou azaindole comme ligands 5-hydroxytryptamine-6
WO2004074243A3 (fr) Heterocyclyl-3-sulfonylindazoles utilises comme ligands de la 5-hydroxytryptamine-6
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
MXPA04003087A (es) Derivados de cromano como ligados de 5-hidroxitriptamina-6.
WO2003049702A3 (fr) Ligands de recepteur vanilloide et utilisation de ceux-ci dans des traitements
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
WO2003053368A3 (fr) Derives de chalcone et leur utilisation dans le traitement de maladies
WO2002092026A3 (fr) Compositions dermatologiques et cosmetiques
WO2004067550A3 (fr) Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
WO2003053359A3 (fr) 1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d&#39;affections
WO2004108715A8 (fr) Benzo[b]thiophenes a substitution 3-aryloxy et 3-heteroaryloxy en tant qu&#39;agents therapeutiques a activite pi3k
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
WO2002085853A3 (fr) Derives de heterocyclylalcoxy-, -alkylthio- et -alkylaminobenzazole en tant que ligands de la 5-hydroxytryptamine-6
CA2474511A1 (fr) Derives de benzofurane et de benzothiophene utilises dans le traitement de troubles hyperproliferatifs
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2002350832A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
EP1455780A4 (fr) Nouveaux derives de benzodifurane imidazoline et de benzofurane imidazoline et leur utilisation pour traiter le glaucome
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
MXPA06000700A (es) Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2426031

Country of ref document: CA

Ref document number: 155443

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2001992697

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002220051

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/003800

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020037006000

Country of ref document: KR

Ref document number: 525592

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002539322

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 1020037006000

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003/04188

Country of ref document: ZA

Ref document number: 200304188

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 200300528

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 018216587

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001992697

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 525592

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 525592

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002220051

Country of ref document: AU